Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally... Show more
Alvotech's third-quarter report arrives as the Icelandic biosimilar developer works to prove its manufacturing turnaround is durable. The first half of 2026 was disrupted by deliberate production slowdowns tied to regulatory remediation, which pressured revenue and pushed the company into quarterly losses. A recovering product line, rising margins, and a stronger adjusted EBITDA figure suggest those operational fixes are beginning to pay off. For investors, the report serves as a key test of whether Alvotech can convert its improving supply capacity into sustained growth ahead of pivotal FDA approval decisions expected in the fourth quarter.
Alvotech reported total third-quarter 2026 revenue of $111.6 million, slightly below the $113.9 million recorded in the same period last year and short of consensus estimates that ranged from roughly $128 million to $139 million. Within that total, product and service revenue rose 78% year over year to $58.2 million, while license and other revenue declined to $53.2 million from $81.1 million a year earlier.
Adjusted EBITDA improved markedly, reaching $31.5 million compared with $14.4 million in the third quarter of 2025, and adjusted operating profit rose to $20.1 million from $4.1 million. For the first nine months of 2026, total revenue was $323.4 million, down from $420.0 million a year earlier, while adjusted EBITDA increased to $78.3 million from $68.0 million. The company's nine-month net loss widened to approximately $140.7 million, versus a profit of roughly $136.5 million in the prior-year period.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and emerging market opportunities more efficiently than manual screening, giving investors a faster way to narrow a broad universe into actionable watchlists.
Sentiment heading into the report was cautious but constructive. Analysts had revised their earnings per share (EPS) estimates lower in the weeks before the release, and the stock has traded well below its average analyst price target, which suggests the market had already priced in a challenging quarter. The revenue shortfall against consensus may weigh on near-term sentiment, but the sharp improvement in adjusted EBITDA and the stronger-than-expected recovery in product revenue could temper downside pressure. Attention now shifts to management's commentary on supply normalization and the timing of pending regulatory decisions.
Looking ahead, the central catalyst for Alvotech is a cluster of FDA decisions on biosimilar applications targeting Simponi, Eylea, and Prolia/Xgeva, which are expected before the end of 2026. Approvals could unlock new U.S. market launches and meaningfully expand the company's commercial opportunity.
Investors should also monitor whether the improvement in product revenue and adjusted EBITDA continues into the fourth quarter. Alvotech has reaffirmed full-year 2026 revenue guidance in the range of $650 million to $700 million, alongside an adjusted EBITDA target of $180 million to $220 million. Delivering on that range will require a strong finish to the year as manufacturing capacity normalizes.
Margin trends, license revenue timing, and the pace of supply ramp-up remain important variables. Because license and other revenue can be lumpy from quarter to quarter, the trajectory of product and service revenue is likely to be the clearest signal of underlying demand. Regulatory outcomes, execution on new launches, and cash generation toward the company's positive free-cash-flow goal are all key factors to watch in the coming quarters.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry PharmaceuticalsGeneric